Keywords: sweden, meda, buys, rights, gsk, relifex, swedish
Sweden's Meda buys rights to GSK's Relifex
Article | 05 September 2001
Swedish specialty pharmaceuticals group Meda AB has acquired licensingrights to GlaxoSmithKline's Relifex/ Relafen (nabumetone), a non-steroidal anti-inflammatory drug for rheumatoid ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
